scorecardresearch
Tuesday, September 23, 2025
TopicCovaxin

Topic: Covaxin

Good news for kids: Expert panel gives Covaxin emergency approval for 2-18-year-olds

The phase 2/3 clinical trials for Covaxin for children were completed last month. The SEC will now send its recommendations to DCGI.

SII, Bharat Biotech get nod to export 10 lakh Covid vaccine doses under ‘Vaccine Maitri’

Ten lakh doses of Covaxin would be sent to Iran and 10 lakh doses of Covishield will be exported each to Myanmar, Nepal & Bangladesh under the ‘Vaccine Maitri’ programme in October.

The three factors influencing India’s December deadline for Covid vaccination

The goal of vaccinating all adults by 31st December 2021 is not as unrealistic as it may have seemed earlier.

Vaccine makers upset over ‘differential pricing’ for ZyCov-D, and lack of clarity on exports

ZyCov-D has reportedly been priced by the company at Rs 1,900 for three doses while the others cost between Rs 205-215 per dose.

Decision on Bharat Biotech’s Covaxin emergency use listing will be made in October, WHO says

The status of assessment for Covaxin is ongoing. Bharat Biotech said it submitted data pertaining to its Covid vaccine to WHO on 19 April and is awaiting feedback for the same.

How Sri Lanka is facing an economic disaster after overnight switch to total organic farming

A selection of the best news reports, analysis and opinions published by ThePrint this week.

Centre places order with Serum Institute of India for 66 crore Covishield doses

SII has enhanced the manufacturing capacity of Covishield to more than 20 crore doses per month, and the latest consignment ordered by Centre is to be supplied by December.

In India’s vaccination race, Covishield at 88% beats Covaxin hands down

Govt data shows that 65.28 crore doses have been administered. Of this, Covaxin accounts for just 12.1% of doses administered.

At 16.4 cr doses, SII’s increased Covishield output helps India cross Aug vaccination target

Modi govt, which projected 15 crore doses would be available in August, managed to achieve its 1 crore-doses-a-day plan last week. Meanwhile, Covaxin production lags.

Bharat Biotech’s Ankleshwar plant, manufacturer of rabies vaccine, rolls out 1st batch of Covaxin

Health Minister Mansukh Mandaviya released the first commercial batch of Covaxin from the Gujarat plant Sunday, said it had the capacity to produce more than 1 crore doses per month.

On Camera

Bads of Bollywood can’t get more brazenly nepo. The joke’s on us

After watching the most discussed series on Netflix, I was planning to write an asterisk-heavy column. As a tribute to the asterisks in its...

Market regulator SEBI clears Adani Group of impropriety alleged by Hindenburg Research

SEBI probe concluded that purported loans and fund transfers were paid back in full and did not amount to deceptive market practices or unreported related party transactions.

India takes a relook at Russian Su-57, but not for its stealth. Here’s why

India exited the Indo-Russian FGFA programme in 2018. But now it might procure at least 2 squadrons of Su-57 aircraft from Russia and evaluate Russian proposal to manufacture them in India.

India doesn’t give walkovers to Pakistan in war. Here’s why it shouldn’t do it in cricket either

Many really smart people now share the position that playing cricket with Pakistan is politically, strategically and morally wrong. It is just a poor appreciation of competitive sport.